MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
MeiraGTx Holdings plc announced that the FDA has granted Breakthrough Therapy Designation for its AAV2-hAQP1 gene therapy targeting Grade 2 and 3 radiation-induced xerostomia. The company also provided updates on multiple clinical programs including Parkinson’s disease and inherited retinal diseases, secured significant collaborations with Eli Lill…